Clinical trials
Peritoneal (Metastatic) Cancer clinical trials
Below are recruiting peritoneal (metastatic) cancer clinical trials, each written for real people, not researchers. We’re tracking 140 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07277413RecruitingPhase 1
Study of IDE892 for advanced solid tumors with MTAP deletion
This study tests a new drug called IDE892, alone or in combination, for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and whether it can shrink tumors.
Santa Rosa, CaliforniaAges 18 years+ - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
Tampa, FloridaAges 18 years+ - NCT06750484RecruitingPhase 2
Testing trastuzumab deruxtecan in HER2-zero breast cancer
This trial tests a new drug called trastuzumab deruxtecan (a targeted antibody-drug combination) for people with advanced breast cancer that never showed any HER2 protein (HER2-zero). The goal is to see if it can shrink tumors and improve outcomes for those who have already had standard treatments.
New Haven, ConnecticutAges 18 years+ - NCT05508464Recruiting
Test targeted radiation to control many metastases safely
This study tests whether a focused, high-precision type of radiation can control many cancer spread-out spots (“metastases”) at the same time, while keeping side effects acceptable. It may help people with many metastases live longer or have better disease control by aiming treatment at every treatable spot.
London, OntarioAges 18 years+ - NCT06024837Recruiting
Testing spectral CT for colorectal cancer spread to liver or belly
This study tests a new type of CT scan (spectral CT) to see how well it detects colorectal cancer that has spread to the liver or belly lining. It may help doctors better plan surgery to remove all the cancer.
Saint-EtienneAges Any age - NCT05285358RecruitingPhase 1
Aerosol chemo plus standard drugs for bile duct and gallbladder cancer
This trial tests a new way to give the drug paclitaxel directly into your belly as a mist, along with two standard chemo drugs given through your veins, for bile duct or gallbladder cancer that has spread to the lining of the belly. The goal is to see if this approach can better control the cancer in the belly.
Duarte, CaliforniaAges 18 years+ - NCT06756035RecruitingPhase 1
Testing CT-95 in advanced cancers with mesothelin
This trial tests a new drug (CT-95) for advanced cancers that have a marker called mesothelin. It's an early-phase study to see if the drug is safe and effective.
Denver, ColoradoAges 18 years+ - NCT05954429RecruitingPhase 2
Study of fruquintinib plus immunotherapy after standard CRC treatment
This trial studies fruquintinib combined with serplulimab (an immune therapy) for advanced colorectal cancer that has spread and is no longer responding to standard treatments. It may help by slowing the cancer’s growth and improving outcomes after the usual options have been tried.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04684459RecruitingEarly Phase 1
CAR-T therapy for tumors with HER2 and PD-L1 markers
This early-phase trial tests CAR-T cells designed to attack tumors that have high HER2 and PD-L1. It may help people with certain solid cancers that have not responded well to standard treatment.
Chengdu, SichuanAges 18–75 - NCT05970705RecruitingPhase 2
Regorafenib plus TAS-102 versus regorafenib alone for advanced bowel cancer
This Phase 2 study tests whether adding TAS-102 to regorafenib works better than regorafenib by itself for metastatic colorectal cancer after at least one prior treatment has stopped working. It aims to improve how long the cancer can be controlled for patients in later treatment lines.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06485713RecruitingPhase 2
Third-line therapy for advanced colorectal cancer
This trial tests a combination of two oral cancer drugs, trifluridine/tipiracil and fufuquitinib, as a third-line treatment for people with advanced colorectal cancer. It may be an option if prior treatments have stopped working.
Wenzhou, ZhejiangAges 18–75 - NCT07257653RecruitingPhase 2
Cetuximab beta plus fruquintinib with or without immunotherapy for first-line advanced colorectal cancer
This trial tests a combination of two targeted drugs (cetuximab beta and fruquintinib) with or without an immunotherapy drug for people with a specific type of advanced colorectal cancer that has not been treated before. It aims to see if this approach is safe and effective for those whose tumors have certain genetic markers (RAS and BRAF wild type).
Hangzhou, ZhejiangAges 10–85 - NCT05753306RecruitingPhase 2
Robot surgery plus heated chemo for limited spread stomach cancer
This study tests a “robot-assisted” surgery to remove stomach cancer in the belly lining (peritoneum) along with heated chemotherapy placed inside the abdomen. It’s for people whose cancer has spread only in the peritoneum, aiming to control disease when there’s a good chance of removing it all.
Rochester, MinnesotaAges 18–80 - NCT07464366RecruitingPhase 2
MRG003 with or without putrelimab for salivary gland cancer
This trial tests a new drug combination (MRG003 with or without putrelimab) for people with advanced salivary gland cancer that has EGFR protein. It aims to see if the treatment is safe and helps shrink tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05985655RecruitingPhase 1/Phase 2
Study of GTAEXS617 for advanced solid tumors
This trial tests a new drug called GTAEXS617 for adults with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT04511039RecruitingPhase 1
New targeted pill combo for advanced colon or stomach cancers
This Phase 1 trial tests a combination of oral (swallowed) drugs—trifluridine/tipiracil plus talazoparib—in people with advanced (locally advanced or metastatic) colorectal or gastroesophageal adenocarcinoma. It’s designed to see how well the treatment can control cancer and to better understand side effects and dosing.
Buffalo, New YorkAges 18 years+ - NCT07133490RecruitingPhase 2
Pressurized intraperitoneal aerosol chemotherapy for advanced stomach cancer
This trial tests a new way to deliver chemotherapy directly into the abdomen using a spray (called PIPAC) in people with stomach cancer that has spread to the lining of the belly. The aim is to see if it can help control the cancer with fewer side effects.
AmsterdamAges Any age - NCT06141265RecruitingPhase 2
Niraparib maintenance after chemo and Avastin for advanced ovarian cancer
This trial tests whether the PARP inhibitor niraparib can help keep advanced ovarian cancer from coming back. You may qualify if you have a BRCA mutation or HRD-positive tumor and finished first-line chemotherapy with bevacizumab (Avastin) with good response.
Beijing, Beijing MunicipalityAges 18–75 - NCT06001255RecruitingPhase 2
Testing HS-20093 for advanced prostate and other solid cancers
This trial is testing a new drug called HS-20093 for people with advanced prostate cancer or other solid tumors that have spread and stopped responding to standard treatments. The drug targets a protein on cancer cells to try to stop cancer growth.
BeijingAges 18 years+ - NCT05278052RecruitingPhase 3
Maintenance therapy alone versus radiation plus maintenance for lung cancer
This trial compares standard maintenance treatment versus adding focused radiation to remaining limited (oligometastatic) spots in the body after initial chemotherapy. It aims to see whether treating those limited spots with radiation can improve outcomes without unacceptable side effects.
Mumbai, MaharashtraAges 18–99 - NCT06749860RecruitingPhase 2
Targeted drug combo for HER2-positive advanced lung cancer
This trial tests a combination of three drugs (Disitamab Vedotin, Tislelizumab, and Bevacizumab) for people with advanced non-small cell lung cancer that has a specific change in the HER2 gene or protein. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
ShanghaiAges 18 years+ - NCT06114511RecruitingPhase 1/Phase 2
Study of BL-M07D1 for HER2-mutated advanced lung cancer
This trial tests a new drug, BL-M07D1, for people with a specific type of advanced non-small-cell lung cancer that has a HER2 mutation. The drug targets cancer cells with this mutation, and the study aims to see if it is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT06674343RecruitingPhase 3
Furmonertinib for advanced lung cancer with EGFR mutations
This trial tests a higher dose of furmonertinib (160mg) as a first treatment for advanced non-small cell lung cancer that has specific EGFR mutations (19Del or L858R). It aims to see if this drug can help shrink tumors and delay disease progression.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04686305RecruitingPhase 1
Test drug T-DXd plus immunotherapy, with or without chemotherapy for HER2+ lung cancer
This Phase 1 study tests the safety (and early effectiveness) of T-DXd combined with immunotherapy, sometimes also with chemotherapy, in people with advanced lung cancer that is HER2-positive. It may help if standard options have been limited or your tumor does not have certain genetic changes that already have targeted treatments.
Duarte, CaliforniaAges 18 years+
Hear when a new Peritoneal (Metastatic) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for peritoneal (metastatic) cancer?
- Yes. Clin2 currently lists 140 recruiting peritoneal (metastatic) cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a peritoneal (metastatic) cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a peritoneal (metastatic) cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.